Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a written consent form before any trial-related procedures take place.
• People aged 18 or older.
• People with a confirmed diagnosis of unresectable locally advanced or metastatic cancer — specifically breast, bladder (urothelial), non-small cell lung, or stomach (gastric) cancer — where a type of treatment called an Antibody-Drug Conjugate (ADC) has been approved or made available through an early access program.
• People who have at least two tumour sites that can be identified: at least one that can be measured on scans according to standard criteria, and at least one (not in bone or brain) that can be safely biopsied.
• People who have a tumour site outside the bone and brain that can be safely biopsied, and who agree to provide tissue samples before and after treatment begins (a recent archived biopsy taken within one month of joining may be accepted in some cases — confirm with trial site).
• People whose life expectancy is estimated by the treating doctor to be at least 12 weeks.
• People with a general health and activity level assessed by the treating doctor as reasonably functional (rated 0, 1, or 2 on a standard medical scale called the ECOG scale).
• People whose blood counts and organ function are considered adequate for receiving an ADC treatment, as assessed by the treating doctor.
• Women who could become pregnant, and men, who agree to use effective contraception throughout the trial and for up to 7 months after finishing treatment (women) or 4 months (men).
• People who are affiliated with a social security system or equivalent health coverage.
• People who are willing and able to follow the trial procedures for its full duration.
• People who agree to allow their tumour tissue and blood samples to be used for future scientific research, including genetic and protein analysis.

Who may not be able to join:

• People who have previously received an Antibody-Drug Conjugate (ADC) as part of a curative (aimed at cure) treatment.
• People who have not agreed to allow their samples to be used for research.
• People who have another serious, rapidly progressing illness that is considered life-threatening in the short term.
• People who are currently receiving treatment for a different cancer or blood disorder at the same time as the ADC treatment in this trial.
• People who have not waited long enough after certain previous treatments before starting the trial — this includes recent brain radiation, chemotherapy, other cancer drugs, immunotherapy, hormonal therapy, major surgery, or radiotherapy covering a large area of the body (specific waiting periods apply to each — confirm with trial site).
• Women who are pregnant, breastfeeding, or planning to become pregnant during the trial or within 90 days after the last dose of the study treatment.
• People who are legally detained, under protective custody, or under guardianship.

Important: Always verify eligibility with the trial site directly before applying.